The Precise Tumor Test simplifies patient care for clinicians by providing straightforward interpretations, prioritization of therapies, and the next steps specific to each patient’s tumor genomic results.
The Precise Tumor Test is a next generation sequencing assay that analyzes more than 500 cancer-related genes, as well as key immuno-oncology biomarkers such as microsatellite instability (MSI) and tumor mutational burden (TMB), with broad coverage of guidelines.1
The Precise Tumor Test combines DNA and RNA sequencing to detect more fusions and splice variants compared to DNA-only tests2-5
The Precise Tumor Test identifies clinically relevant DNA and RNA variants to help guide personalized treatment decisions. By focusing on key guideline-recommended biomarkers and emerging pan-cancer targets, the Precise Tumor Test enables comprehensive and confident treatment planning.
Provider completes the test request form (in the EMR system, portal or via paper TRF)
Our laboratory processing staff will contact your pathology partner directly to obtain the tumor sample for Precise Tumor Testing
Results will be reported in the provider portal as they become available
If you already count on the MyRisk Test, you’ll soon have even more reason to choose Myriad.
We’re bringing Precise Tumor Molecular Profile Test, MyChoice® CDx Myriad HRD Companion Diagnostic Test, and immunohistochemistry (IHC) testing for PD-L1 and FOLR1/FRa into your preferred EMR system workflow, so you can order germline and tumor genomic tests in one seamless process, from a single lab.
For a complete approach to cancer risk management and treatment planning, Precise Tumor can be combined with The MyRisk Test and appropriate tumor test to deliver powerful results informing patient care across the entire journey-from assessing hereditary cancer syndromes to guiding treatment decisions.
Combine germline and tumor genomic insights to identify hereditary cancer risks and actionable gene variants, enabling personalized treatment plans and targeted therapies. The MyRisk Test and the Precise Tumor Test focus on clinically relevant variations in the genome, where each test couples RNA analysis with DNA sequencing to provide more refined interpretation of results.
Integrate germline and tumor genomic profiling with HRD testing to identify more patients most likely to benefit from PARP inhibitors. The Precise Tumor Test and the MyChoice Test deliver a powerful combination of actionable tumor genomic information and homologous recombination status, optimizing treatment strategies for ovarian cancers.
For your patients with early-stage breast cancer, pair germline testing with tumor genomic insights and breast cancer recurrence assessment to help guide personalized decisions on risk-reducing surgeries and adjuvant therapy strategies.
The Precise Tumor Test simplifies patient care for oncologists by providing straightforward interpretations, prioritization of therapies, and the next steps specific to each patient’s genomic results.
The Precise Tumor Test combines DNA and RNA sequencing to detect more fusions and splice variants compared to DNA-only tests.2-5 Precise Tumor is validated to 98.91% analytical sensitivity and >99.99% analytical specificity.1
Transparent pricing for genetic results with financial assistance and other affordability options.
©2025 Myriad Genetics, Inc., Myriad Genetics, Myriad Oncology, MyRisk, Precise Tumor, MyChoice, Prolaris, BRACAnalysis CDx, RiskScore, and their respective logos, are either trademarks or registered trademarks of Myriad Genetics, Inc and its subsidiaries in the United States and other jurisdictions. Eurobio Scientific has licensed the EndoPredict test to Myriad Genetics in select territories.